Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 13
Submit an article Journal homepage
446
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Health-related quality of life in transplant eligible multiple myeloma patients with or without early ASCT in the real-world setting

Mir M. Asrara Clinical Research Unit, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, IndiaORCID Iconhttps://orcid.org/0000-0001-7754-9657
ORCID Icon,
Deepesh P. Ladb Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, IndiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3754-7774
ORCID Icon,
Dipika Bansala Clinical Research Unit, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, IndiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4520-3293
ORCID Icon,
Shankar Prinjac Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Alka Khadwalb Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Gaurav Prakashb Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Arihant Jainb Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Aditya Jandialb Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
&
Pankaj Malhotrab Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
 show all
Pages 3271-3277 | Received 30 Mar 2021, Accepted 04 Jul 2021, Published online: 16 Jul 2021

References

  • Jain T, Sonbol MB, Firwana B, et al. High-dose chemotherapy with early autologous stem cell transplantation compared to standard dose chemotherapy or delayed transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2019;25(2):239–247.
  • Dhakal B, Szabo A, Chhabra S, et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol. 2018;4(3):343–350.
  • Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–1320.
  • Kumar SK, Lacy MQ, Dispenzieri A, et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer. 2012;118(6):1585–1592.
  • Roussel M, Hebraud B, Hulin C, et al. Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Leuk Lymphoma. 2020;61(6):1323–1333.
  • Kumar SK, Buadi FK, Rajkumar SV. Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing. Blood. 2019;133(7):652–659.
  • Schriber JR, Hari PN, Ahn KW, et al. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report. Cancer. 2017;123(16):3141–3149.
  • Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group Consensus Criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
  • Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
  • Cocks K, Cohen D, Wisløff F, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43(11):1670–1678.
  • Sully K, Trigg A, Bonner N, et al. Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients. Eur J Haematol. 2019;103(5):500–509.
  • Cocks K, King MT, Velikova G, et al. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2011;29(1):89–96.
  • Chakraborty R, Hamilton BK, Hashmi SK, et al. Health-related quality of life after autologous stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2018;24(8):1546–1553.
  • Abonour R, Rifkin RM, Gasparetto C, et al. Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect(®) MM Registry. Br J Haematol. 2020;193(1):93–100.
  • Nooka A, Jimenez-Zepeda V, Boise L, et al. RVD is a superior induction regimen compared to VCD among transplant-eligible myeloma patients. Clin Lymph Myeloma Leuk. 2017;17(1):e137–e138.
  • Youron P, Singh C, Jindal N, et al. Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ-C30 and QLQ-CLL17 questionnaire. Eur J Haematol. 2020;105(6):755–762.
  • Pandya C, Hashmi S, Khera N, et al. Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma. Clin Transplant. 2014;28(10):1084–1091.
  • 2021. Available from: https://pmjay.gov.in/sites/default/files/2020-01/HBP_2.0-For_Website_V2.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.